Form 4: Century Therapeutics Officer Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock at an average price of $3.0979 under a pre-arranged trading plan.
Summary
- Gregory Russotti, a key officer at Century Therapeutics, sold 5,000 shares of the company's common stock on April 22, 2024.
- The sale was executed under a Rule 10b5-1 trading plan adopted on January 9, 2024.
- The shares were sold at prices ranging from $2.98 to $3.37, with a weighted average price of $3.0979.
- Following the transaction, Russotti directly owns 297,319 shares and indirectly owns 92,773 shares through the Gregory Russotti 2021 Family Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by an officer. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Future Outlook
NA
Industry Context
Sales by company insiders are common and must be reported to the SEC. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on inside information.
Key Dates
| Date | Description |
|---|---|
| 01/09/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 04/22/2024 | Date of stock sale transaction |
| 04/24/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.